Search
Akebia Therapeutics Inc
AKBAAdd to Watchlist
0.911USD
+0.046+5.32%
Close 10-05 16:00（ET）
244.38MMarket Cap
LossP/E TTM
Akebia Therapeutics Inc (AKBA) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Akebia Therapeutics Inc in the past month.
Buy
3 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
3.917USD+352.79%
AKBA Analyst Recommendation Trends
In the current month, AKBA has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AKBA average Analyst price target in the last month is 3.917.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
5
5
5
5
AKBA Analyst Rating for Peer Comparison
Updated: Oct 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Regeneron Pharmaceuticals Inc
REGN
6
15
10
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, AKBA EPS is projected to reach -0.037 in FY2026Q3, following reported EPS of -0.033 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.03
-0.03
-0.04
-0.04
-0.04
Actual
-0.05
-0.03
-0.03
--
--
Surprise
-84.48%
-21.07%
+24.91%
--
--
FAQs
What is Akebia Therapeutics Inc's expected revenue for the next quarter?
Akebia Therapeutics Inc's expected revenue is 46.94M.
What is Akebia Therapeutics Inc's price target?
Analysts forecast that Akebia Therapeutics Inc's price target is USD 3.92, with the highest forecast at USD 6.00 and the lowest forecast at USD 1.00.
How have Akebia Therapeutics IncAKBA's recent earnings per share performed?
The market expectation was USD -0.03, while Akebia Therapeutics IncAKBA's earnings per share (EPS) for the previous quarter was USD -0.03. EPS for the next quarter is expected at USD -0.04.
What is the analyst rating for Akebia Therapeutics Inc?
Based on the ratings of Akebia Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.